Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $36.2M | $0 | $0 | $0 | $309.0K |
| Cost of revenue | $1.4M | $3.8M | $5.2M | $18.1M | $782.0K | $0 | $0 | $0 |
| Gross profit | −$1.4M | −$3.8M | −$5.2M | $18.1M | −$782.0K | $0 | $0 | $309.0K |
| Gross margin | — | — | — | 50.0% | — | — | — | 100.0% |
| R&D | $155.0M | $285.4M | $261.1M | $229.9M | $0 | $0 | $0 | $0 |
| Operating income | −$231.7M | −$336.0M | −$608.5M | −$83.5M | −$41.2M | −$27.0M | −$201 | −$2.4M |
| EBITDA | −$230.3M | −$334.3M | −$615.7M | −$603.9M | −$40.5M | −$12.1K | −$201.0K | −$2.4M |
| Net income | −$229.6M | −$337.5M | −$633.2M | −$626.5M | −$110.6M | −$26.0M | −$298 | −$859.0K |
| Net margin | — | — | — | -1731.1% | — | — | — | -278.0% |
| EPS (diluted) | -11.47 | -16.87 | -22.32 | -2247.53 | -3.14 | -0.00 | -8.00 | -21.00 |
Annual figures · source: Financial Modeling Prep
STRATEGIC PARTNERS A/S
No one on the platform currently holds OZYMF.
No tracked institution reports a position in OZYMF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-12-06 | 1-for-1000reverse |
No one on the platform has traded OZYMF yet.
| $63132 |
| — |
| QBIOQ BioMed Inc. | $0.00 | -0.00% | $14509 | — |
| SDCCQSmileDirectClub Inc Class A | $0.00 | +0.00% | $13395 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Big updates for #Orphazyme investors! Settlement distribution is underway, with an average payout of $760 so far. Make sure to check your email if you filed with @11thestate! $ORPH $OZYMF
View on StockTwits ↗$ORPH $OZYMF settles for $2.5 million with investors to resolve claims regarding misleading statements made during its 2020 IPO. And you can still file for it. #Orphazyme #ORPH Case page:https://11thestate.com/cases/orphazyme-ipo-settlement "The Complaint alleges Offering Documents were negligently prepared and contained untrue statements. Defendants made false/misleading statements about arimoclomol's effectiveness and FDA approval prospects. This resulted in materially false public statements."
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.